title: Recent development in studies of tetrahydroprotoberberines: mechanism in antinociception and drug addiction.
abstract: The tetrahydroprotoberberines (THPBs) are compounds isolated from Chinese herbs that possess a unique pharmacological profile as D2 dopamine receptor antagonists and D1 receptor agonists. l-Tetrahydropalmatine (l-THP) and l-stepholidine (SPD), members of the THPB family, were shown to have potential clinical use in the treatment of pain. However, their mechanism of action is not clear. In the past decades, Chinese scientists have made a great deal of effort to explore the mechanisms by which the THPBs and its analogues elicit antinociception and their potential utility in treating drug abuse. It is now clear that the antinociception produced by l-THP is related to inhibition of D(2) dopamine receptors. The present review focuses on the recent progress made in understanding the mechanisms of l-THP- and l-SPD-mediated antinociception and the sequel of drug addiction.
authors: State Key laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Rm# 2-315, Shanghai 201203, China.
authors: Hongyuan
authors: H
authors: Chu
authors: Guozhang
authors: G
authors: Jin
authors: Eitan
authors: E
authors: Friedman
authors: Xuechu
authors: X
authors: Zhen
mesh_terms: D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001599:Berberine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D001600:Berberine Alkaloids / Q000494:pharmacology* / Q000627:therapeutic use*; D018492:Dopamine Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008954:Models, Biological; D010146:Pain / Q000188:drug therapy*; D011954:Receptors, Dopamine / Q000378:metabolism / Q000502:physiology; D019966:Substance-Related Disorders / Q000188:drug therapy* / Q000534:rehabilitation
chemical_list: D000700:Analgesics; D001600:Berberine Alkaloids; D018492:Dopamine Antagonists; D011954:Receptors, Dopamine; D001599:Berberine; C010513:stepholidine; C014845:berbine
references: Pain. 2004 Jul;110(1-2):246-9
references: 15275774
references: Biochem Pharmacol. 1997 Jul 15;54(2):233-40
references: 9271327
references: Methods Find Exp Clin Pharmacol. 2000 Jan-Feb;22(1):37-41
references: 10791293
references: Trends Pharmacol Sci. 2002 Jan;23(1):4-7
references: 11804640
references: Pharmacol Biochem Behav. 1998 Jan;59(1):77-82
references: 9443539
references: Med Clin North Am. 1997 Jul;81(4):909-25
references: 9222260
references: Adv Exp Med Biol. 1995;363:27-8
references: 7618527
references: Sheng Li Xue Bao. 1964 Mar;27:47-58
references: 14184587
references: Drug Alcohol Depend. 1998 Jun-Jul;51(1-2):13-22
references: 9716927
references: J Pharmacol Exp Ther. 2000 Jun;293(3):1017-26
references: 10869406
references: Neuron. 2002 Oct 10;36(2):229-40
references: 12383779
references: Lancet. 1996 Feb 24;347(9000):504-8
references: 8596268
references: Acta Pharmacol Sin. 2000 May;21(5):439-44
references: 11324443
references: Zhongguo Yao Li Xue Bao. 1999 Aug;20(8):715-9
references: 10678104
references: Neuropharmacology. 2007 Feb;52(2):355-61
references: 17027045
references: Harv Rev Psychiatry. 2004 Nov-Dec;12(6):305-20
references: 15764467
references: J Pharmacol Exp Ther. 1989 Jun;249(3):769-74
references: 2567351
references: Zhongguo Yao Li Xue Bao. 1986 Nov;7(6):522-6
references: 2955641
references: Pharmacol Biochem Behav. 2003 May;75(2):289-94
references: 12873618
references: Arch Int Pharmacodyn Ther. 1996 Jan-Feb;331(1):74-93
references: 8896712
references: Zhongguo Yao Li Xue Bao. 1986 Jul;7(4):311-4
references: 2954388
references: Sci China B. 1992 Jun;35(6):688-96
references: 1510818
references: Neurosci Biobehav Rev. 2006;30(2):215-38
references: 16099045
references: Physiol Bohemoslov. 1990;39(5):395-401
references: 1965232
references: Zhongguo Yao Li Xue Bao. 1982 Dec;3(4):217-20
references: 6219534
references: Pharmacol Biochem Behav. 2001 Apr;68(4):783-7
references: 11526977
references: Brain Res. 2000 Feb 14;855(2):260-6
references: 10677598
references: Psychopharmacology (Berl). 1996 May;125(2):97-104
references: 8783382
references: Psychopharmacology (Berl). 1999 Mar;143(1):102-10
references: 10227086
references: Zhongguo Yao Li Xue Bao. 1999 Mar;20(3):193-200
references: 10452091
references: Gen Pharmacol. 1999 Apr;32(4):517-22
references: 10323495
references: Zhongguo Yao Li Xue Bao. 1997 May;18(3):225-30
references: 10072938
references: Zhongguo Yao Li Xue Bao. 1989 Mar;10(2):104-10
references: 2530755
references: Psychopharmacology (Berl). 1998 Jan;135(1):99-106
references: 9489939
references: Eur J Pharmacol. 1997 Jul 9;330(2-3):109-13
references: 9253942
references: J Pharmacol Exp Ther. 1997 Oct;283(1):29-38
references: 9336305
references: Trends Pharmacol Sci. 1994 Oct;15(10):374-9
references: 7809953
references: Eur J Pharmacol. 2006 Sep 28;546(1-3):40-7
references: 16905131
references: Psychopharmacology (Berl). 1997 Oct;133(3):283-92
references: 9361335
references: Zhongguo Yao Li Xue Bao. 1992 Jan;13(1):17-22
references: 1605028
references: Neurochem Int. 1992 Mar;20 Suppl:175S-178S
references: 1365421
references: Brain Res. 2003 Oct 17;987(2):135-43
references: 14499957
references: Nature. 1983 Oct 6-12;305(5934):529-30
references: 6621700
references: Behav Brain Res. 1999 Jun;101(2):129-52
references: 10372570
references: Science. 1997 Oct 3;278(5335):45-7
references: 9311924
references: Psychopharmacology (Berl). 2007 Jul;192(4):581-91
references: 17361394